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Cell-based therapy – navigating troubled waters
Michael S Pepper
Cells and engineered tissue can be used to treat an increasing 
number of diseases. This development, together with 
promising pre-clinical data in regenerative medicine, has raised 
the expectations of many patients. However, this situation 
tends to make people vulnerable to the lures of companies 
that abuse the stem cell promise. The problem is compounded 
by people’s propensity to believe that the healing powers of 
positive thinking, large sums of money and foreign institutions 
are greater than those of therapies developed through well-
tested, properly constructed clinical trials.
Stem cell therapy has been proposed for many diseases, 
including diseases of the central nervous system (spinal cord 
injury, Alzheimer’s disease, Parkinson’s disease, cerebral palsy, 
multiple sclerosis), diabetes and heart disease (post-myocardial 
infarction, cardiac failure). Several clinical trials have shown 
an improvement in left ventricular ejection fraction in patients 
with cardiac disease, following stem cell administration (intra-
coronary or intramyocardial). However, for most of the other 
diseases mentioned, there are no firm clinical data to justify the 
routine use of stem cells for their treatment.
Cell-based therapy, however, has been used very successfully 
in a few settings. The most universally accepted form of cell 
therapy is bone marrow transplantation (BMT), which has 
been practised for more than 50 years. Most of its indications 
have been repeatedly tested and verified through rigorously 
controlled clinical trials. Other currently applied forms of 
cell-based therapy include treating burns, dermal and corneal 
wounds, and orthopaedic problems.
Questionable practices
The global emergence of centres that purport to treat many 
human diseases using stem cells has generated confusion in 
the health care market. Many of these centres operate on the 
following basis:
•    emotionally vulnerable patients are lured into a clinic, often 
via a website that promises miraculous cures for a large 
number of diseases
•    clever marketing and careful evasion of the truth often 
underlie their immediate and superficial appeal 
•    anecdotal evidence is provided, indicating how patients 
with similar diseases have been cured, often contrary to 
their medical practitioners’ predictions (e.g. X was only 
given 3 months to live – and look at him now!)
•    patients (or their parents) are charged excessively for these 
procedures, and must also cover the cost of travel and 
accommodation at sites that are frequently far from their 
homes
•    no sound clinical data support these treatments, and 
repeated requests for data are usually either ignored or 
anecdotal evidence or a variety of disclaimers are provided, 
including the fact that the success of the treatment cannot 
be guaranteed.
Some companies are conducting ‘clinical trials’ that appear 
to be phase I in nature. However, the fact that there have 
(apparently) been no significant adverse reactions to the 
delivered products does not imply that a therapeutic effect 
has been attained. Any therapeutic effect would have to be 
specifically demonstrated. While the cells that are administered 
by these companies may do no harm, their healing properties 
still need to be demonstrated. Expensive treatments cannot 
simply be administered on the basis that they do no harm. 
Furthermore, the psychological impact of these therapies and 
the resulting placebo effect should not be underestimated, 
particularly when patients who pay large sums of money for 
novel forms of therapy strongly believe that their ailments will 
be healed. Inevitably, however, disappointment sets in as the 
placebo effect wears off.
The use of cells the side-effects of which have not been 
adequately studied could also have serious consequences. 
It appears that the less differentiated and more pluripotent 
the cells used for treatment, the greater is the probability 
that they will undergo malignant transformation. A dramatic 
example was a young boy who developed a multi-focal brain 
tumour following intracerebellar and intrathecal injection of 
human fetal neural stem cells for ataxia telangiectasia.1 After 
three treatments (at ages 9, 10 and 12) at a clinic in Russia, 
he developed headaches caused by tumours at the sites of 
injection, which were found to have originated from the 
injected cells. At surgical removal, several satellite tumours 
were also found. The safety profile of the injected cells had not 
been adequately tested prior to administration, and there were 
no experimental/pre-clinical or clinical data to suggest that 
stem cells might be of benefit in ataxia telangiectasia.2
Another bedevilling issue is whether patients in these 
settings should pay for their treatments, which are essentially 
experimental in nature and could be seen as a form of clinical 
trial. In the absence of specific legislation, a case can be made 
for charging patients for routine blood and urine tests (several 
are required on the abovementioned websites). Ethically, 
however, it is highly questionable whether patients should 
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be made to pay for treatments which have no, or limited, 
proven clinical benefit. Large sums of money change hands in 
these settings, and there are currently no universally agreed 
upon fee structures for the treatments. The vulnerability and 
determination of the affected individuals are indicated by the 
lengths to which they will go to raise the money needed, often 
to the detriment of close family members.
In response to these issues, scientists and health professionals 
around the world have published comments and guidelines 
on what should be considered ethical and fair in cell-based 
therapy.2-7 In 2008, the International Society for Stem Cell 
Research published Guidelines for the Clinical Translation of 
Stem Cells (available at http://www.isscr.org/clinical_trans), 
which ‘provides a framework for the responsible and timely 
development of clinically useful stem-cell-based therapies’.8 
Furthermore, several papers published in Nature Reports Stem 
Cells severely criticised the growing commercial exploitation 
of patients through the use of untested and unproven so-called 
‘stem cell therapies’.9-12 These reports emphasise the same 
critical point, that it is immoral and unethical to propose ‘stem 
cell therapy’ to patients if objective clinical improvement in a 
well-structured, documented, and approved clinical trial is not 
provided.
South Africa has not been spared these questionable 
practices, and the legal process against an alleged international 
stem cell scam (in which stem cells were offered to paralysed 
and terminally ill patients across Europe and the USA) appears 
to have stalled on technicalities.13 We must ensure that South 
Africa does not allow the unethical administration of untested 
‘stem cell therapies’ to emotionally vulnerable patients 
desperate for a cure. We can only become part of the global cell 
therapy fraternity on the basis of clinically proven stem cell 
therapies, currently limited to bone marrow transplantation 
(BMT), wounds/ulcers and orthopaedic conditions.
The legislative vacuum in South Africa
Chapter 8 of the National Health Act (the major part of the 
legislation in South Africa that deals with the issue of cell-
based therapy) has not been promulgated. This is a serious 
hiatus, since we have to rely on the outdated Human Tissue 
Act of 1983 to provide the necessary legislation. To compound 
the problem, the legislation in Chapter 8 is confusing and 
incomplete. The situation is attractive for companies wishing to 
set up cell-based therapy activities, as it creates an opportunity 
to establish therapies that might have been prevented by 
more comprehensive and restrictive legislation. However, the 
following should be borne in mind:
•    Chapter 8 is being revised, and regulations will provide 
clear guidelines on what is permissible and what is not. 
Companies may not need to deal with this now, but it will 
become a reality when the legislation comes into force. A 
defined time interval will allow companies to comply with 
the new legislation.
•    Any form of therapy that is not established or that is 
experimental in nature will require the blessing of the 
Medicines Control Council (or its revised equivalent) before 
it can be administered.
•    All clinical trials will have to be scrutinised by an ethics 
committee.
Conclusion
Although there is unquestionable benefit to be derived from 
cell-based therapy, most of this (with the exception of BMT) 
still lies in the future, i.e. it is not part of the current reality 
of stem cells but rather in the realm of the still unproven, but 
nonetheless hope-generating, future promise. Urgent attention 
is being given to regulatory matters in cell therapy and all 
areas that fall under the umbrella of human tissues. Until this 
legislation is in place, health professionals should be aware 
of the questionable nature of the current treatments being 
offered to patients, and advise them appropriately to prevent 
disappointment, unwanted side-effects and unnecessary 
expense.
We certainly can envisage a world in which the promise 
of stem cells will be realised. Hope is a powerful tool in the 
maintenance of physical, emotional and spiritual health; but 
we should also strive to maintain a balance between reality 
and fantasy. If we allow the one to spill over into the other, 
we render ourselves vulnerable to the seductive lure of 
unscrupulous, dishonest and unethical practices.
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